CEL-SCI CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.44 USD | -0.69% |
|
-7.69% | -47.06% |
| Apr. 23 | CEL-SCI Corporation Appoints Mario Gobbo as Board of Directors | CI |
| Feb. 14 | CEL-SCI Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023 | CI |
Presenter SpeechGeert Kersten (Executives)My name is Geert Kersten. I'm the CEO of CEL-SCI Cor...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers, and Ligand Epitope Antigen Presentation System (LEAPS), with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikines rationale for use is to incite a locoregional immune response against the tumor.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.44
USD
Average target price
7.7
USD
Spread / Average Target
+434.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -47.06% | 77.73M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- CVM Stock
- News CEL-SCI Corporation
- Transcript : CEL-SCI Corporation - Special Call
